Glenmark Pharmaceuticals Ltd. Fundamental & Technical Research, Share Price Today

NSE : GLENMARK
NIFTY : NIFTY Midcap 100
NIFTY SECTOR : Nifty Pharma

About Company

Glenmark Pharmaceuticals Limited is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.

Market Cap. ₹43,605 Cr.

52 Week - High/Low ₹1,831/975

P/E Ratio 7.18

P/B Ratio 1.90

Enterprise Value ₹46,763 Cr.

ROE % 25.3

RSI Value 63.47

EMA 50 1458.37

EMA 200 1429.13

Net Profit 5,167 Cr.

Net Profit 3year growth 213.27 Cr.

Net Profit 3 year (back) 1,649 Cr.

Debt to Equity 0.03 %

EPS Growth TTM 1358.88 %

Current Ratio 1.08 %

100 Day SMA 1,488 Rs.

200 Day SMA 1,524 Rs.

21 Day SMA 1,445 Rs.

50 Day SMA 1,428 Rs.

Book Value 814 Rs.

EV/EBITDA Ratio 5

QoQ EPS Growth -30 %

QoQ Operating Profit Growth -37 %

QoQ Sales Growth -15 %

Sales Latest Quarter 2,209 Cr.

YoY Sales Growth 65 %

Market Cap. ₹43,605 Cr.

52 Week - High/Low ₹1,831/975

P/E Ratio

P/B Ratio 5.56

Enterprise Value ₹41,588 Cr.

ROE % -21.18

RSI Value 63.47

EMA 50 1458.37

EMA 200 1429.13

Net Profit -1,502 Cr.

Net Profit 3year growth 51.48 Cr.

Net Profit 3 year (back) 970 Cr.

Debt to Equity 0.13 %

EPS Growth TTM -75.3 %

Current Ratio 1.28 %

100 Day SMA 1,488 Rs.

200 Day SMA 1,524 Rs.

21 Day SMA 1,445 Rs.

50 Day SMA 1,428 Rs.

Book Value 278 Rs.

EV/EBITDA Ratio 15

QoQ EPS Growth -2 %

QoQ Operating Profit Growth -0 %

QoQ Sales Growth -1 %

Sales Latest Quarter 3,302 Cr.

YoY Sales Growth 35 %

Add Parameters

Valuation

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages